Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Arimoclomol (Primary)
- Indications Niemann-Pick disease type C
- Focus Registrational; Therapeutic Use
- Sponsors Orphazyme
- 24 Oct 2017 According to an Orphazyme media release, results of this trial expected in Q3 2018. This study, if positive, will form the basis for a single study filing for NiemannPick Disease Type C, as reported in an Orphazyme media release. The company expects to complete this trial by the end of 2020.
- 07 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2020.
- 07 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.